Does one microbiome make a difference? How is it affected by the health status or lifestyle? As we endeavor the uncharted jungle of the human microbiome, many questions arise and this complex interconnection is not trivial to decipher. While time is limited, IMGMs enteralis analysis service enables you to spend most of your time exploring.
enteralis is a turnkey solution for gut microbiome analysis. It helps customers to tackle crucial decisions during their microbiome analysis by providing the best available tools. We have developed our metagenomics service to a stable routine, offering fast turnaround times of 10 working days for single samples. IMGM's proven expertise with metagenomics projects also enables us to offer upscaled solutions for big studies.
enteralis is developed in cooperation with the MVZ Martinsried and Smartgene in order to combine high levels of medical, scientific and bioinformatics expertise to provide customers with the best options for microbiome analysis.
Sample kits, medical guidance and reporting are provided by the medical experts from the MVZ Martinsried, holding vast expertise in human genetic and microbiological analyses. Sequencing analysis is performed at IMGM using validated protocols for human gut microbiome analysis. Bioinformatic analysis uses the 16S centroids method developed by Smartgene, which is used for microbial identification since 1998.
With the expertise of three dedicated partners, enteralis combines fast turnaround times with validated high quality methods and extensive analysis. As enteralis addresses only the analysis of human gut samples, further products are under development for the different niches of the human microbiome.
IMGM Laboratories took part in the B2Run series in Munich’s Olympiapark
Every starter meant a contribution to a good cause!
On July 14, 2016, IMGM Laboratories participated in the B2Run series in Munich’s Olympiapark with a team of 7 employees completing the 6.2 km circuit.
CFFQuant: determination of the fetal DNA fraction in maternal blood
Low fetal fraction is one of the most common causes of false negative results of next generation sequencing (NGS) -based non-invasive prenatal testing (NIPT). Therefore, it is very important to assure that the maternal cell-free DNA contains enough fetal DNA for analysis of genetic anomalies. Current NGS-based NIPT analyses do not include quantification of fetal fraction for result confirmation.
Therefore, IMGM developed a methylation-specific qPCR assay in cooperation with the MVZ Martinsried which detects as little as 4% of fetal DNA in only 1.5 ng of maternal plasma DNA. CFFQuant is performed twice a week to guarantee a short turn-around time of in average three working days.
Quantification of the fetal DNA fraction is not an add-on for NIPT but a requirement for reliable results.
About IMGM Laboratories GmbH
IMGM is a leading genomic service provider with a focus on Biomarker Discovery, Biodistribution, Pharmacogenetics and Metagenomics. With NGS, microarray and qPCR state-of-the-art technology as well as competency in complex data analysis the company offers tailored solutions to customers from pharma, diagnostics, biotech and academia. Quality, experience, motivation and a strong background in molecular genetics and medical diagnostics make IMGM a valuable partner for genetic analysis in pre-clinical and clinical studies.
Get in touch with our team via our contact sheet or call +49.89.4524667.0. For more information on IMGM’s service portfolio check out our homepage www.IMGM.com